Contrasting Precigen (PGEN) and Its Rivals

Precigen (NASDAQ:PGEN) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Precigen to related businesses based on the strength of its institutional ownership, analyst recommendations, profitability, valuation, risk, dividends and earnings.

Insider and Institutional Ownership

33.5% of Precigen shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 41.4% of Precigen shares are owned by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Precigen has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500. Comparatively, Precigen’s peers have a beta of 1.11, indicating that their average share price is 11% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Precigen and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precigen	1	1	4	0	2.50
Precigen Competitors	9773	15031	45238	1571	2.54

Precigen currently has a consensus target price of $13.67, suggesting a potential upside of 96.93%. As a group, “Biotechnology” companies have a potential upside of 95.47%. Given Precigen’s higher possible upside, research analysts plainly believe Precigen is more favorable than its peers.

Profitability

This table compares Precigen and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Precigen	-183.98%	423.75%	84.39%
Precigen Competitors	-9,054.31%	-198.21%	-30.53%

Earnings & Valuation

This table compares Precigen and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Precigen	$9.68 million	-$250.64 million	-6.67
Precigen Competitors	$689.46 million	$10.37 million	-10.05

Precigen’s peers have higher revenue and earnings than Precigen. Precigen is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Summary

Precigen beats its peers on 7 of the 13 factors compared.

About Precigen

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.